ROS1 and cholangiocarcinoma: The purpose of this study was to gain further insight into the relationship and interplay between the expression of ALK, cMet, and ROS1 and the cytotoxicity of crizotinib, ceritinib, and capmatinib in cholangiocarcinoma cells.